다분할 방사선치료에 의한 3기 비소세포성 폐암의 치료
Concomitant Boost Radiotherapy in Clinical Stage III Non-Small Cell Lung Cancer
대한암학회지 1994년 26권 5호 p.778 ~ 785
박찬일, 신경환,
소속 상세정보
박찬일 ( )
서울대학교 치과대학 교정학교실
신경환 ( )
서울대학교
KMID : 0360319940260050778
Abstract
A single treatement arm, phase I/Ⅱtrial was performed to determine the tumor response to concomitant boost radiotherapy and to assess the toxic effects of this techneque in patients with stage Ⅲ NSCLC.
Between 1991-1992, 52 patients with stage ⅢNSCLC were treated according to the concomitant boost technique. The large fields including primary mass and mediastinum received a dose of 54Gy in 30 daily fractions. The boost dose(13 Gy) was
administered
concomitantly with the last ten fractions of the large fields treatment, with a 6 hour interval. The maximal allowed dose to the spinal cord was 45Gy.
At a median follow-up of 13 months, complete remission was achieved in 15 patients (28.8%) and a partial remission in 28 aptients(53.8%). The overall survival rate at 2 year was 19.9%. The median survival time was 13 months. The survival rates
were
28%
and 16% for the complete responders and partial/non responders. Grade 1 and 2 esophagitis occurred in 86.5% and 13.5% of the patients. respectively. The clinical or radiologic condition of 38 patients (73.1%) was compatible with radiation
pneumonitis
but no patients showed severe symptoms. Late complications have been limited to radiologically detected lung fibrosis in 12(23.1%) patients.
The results so far appeared to be better than the outcome of conventional radiotherapy. Its real value will be determined in a prospective randomized study.
키워드
원문 및 링크아웃 정보
등재저널 정보